Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of methazolamide in preparing medicament for treating ankylosing spondylitis

Ankylosing spondylitis, methazolamide technology, applied in the application field of medicine, can solve problems such as kidney damage, spine and tendon end disease, poor effect, synovial membrane effect rarely reported, etc.

Inactive Publication Date: 2010-07-28
常晓天 +3
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these drugs have side effects such as edema, hematuria, gastrointestinal reactions and kidney damage
[0006] (2) Sulfasalzine (SSZ): This type of drug is an azo compound of 5-aminosalicylic acid and sulfapyridine, which is mainly effective for the peripheral joints of patients, but not effective for spinal and tendinopathy
However, so far, most of the studies on ankylosing spondylitis have focused on the diseased bone tissue, and there are few reports on the role of the synovium in the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of methazolamide in preparing medicament for treating ankylosing spondylitis
  • Application of methazolamide in preparing medicament for treating ankylosing spondylitis
  • Application of methazolamide in preparing medicament for treating ankylosing spondylitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: In order to explore the pathogenesis of ankylosing spondylitis, the inventors of the present invention used proteomics technology to study the synovial tissue of patients with ankylosing spondylitis.

[0026] In order to discover the specific pathogenic protein factors of ankylosing spondylitis, synovial tissues of osteoarthritis and rheumatoid arthritis were used as controls. Osteoarthritis is degenerative bone damage in the elderly, and rheumatoid arthritis is an autoimmune disease. Although both are manifested as arthritis, using the two as a control can effectively remove proteins that are only related to bone damage and immunity, and find proteins specifically expressed in ankylosing spondylitis. It is rare to compare three diseases at the same time in proteomics research.

[0027] Methods: Firstly, the total protein of diseased synovial tissue (10 specimens for each disease) was extracted according to the conventional method, and the protein concentrat...

Embodiment 2

[0034] Embodiment 2: clinical treatment

[0035] Patient Information: Two patients with ankylosing spondylitis (referred to as patient S and patient L) were screened. The patients were at similar stages of disease progression. The diagnosis was based on the New York criteria revised in 1984. The above two patients met the characteristics of mid-stage ankylosing spondylitis according to the following staging diagnostic criteria, namely ① Pain in the neck, back, waist, hip, knee, shoulder, sternoclavicular joint, intercostal nerve, sacrohip joint, limited mobility, and mild ②X-ray films showed destruction of the sacrohip joint surface, blurred joint edges, and narrowed gaps; ③Laboratory tests showed increased erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). All three criteria are met. The patient had no history, symptoms or sequelae of iritis, and the rheumatoid factor RF was negative. The patient had previously received the above-mentioned conventional tre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a new application of methazolamide, in particular to application in preparing a medicament for treating ankylosing spondylitis. In a concrete application method, a patient orally administrates two methazolamide tablets of 25mg every day after a meal respectively in the morning and at night; and the methazolamide takes effect commonly for one month and can obviously improve and reduce BASDAI and BASFI of the ankylosing spondylitis, lighten neck ache, back ache and hip ache, reduce morning stiffness time and ache joint number and obviously lower the blood sedimentation and immune globulin level of the patient.

Description

technical field [0001] The invention relates to a new medical application of methazolamide, namely the application in the preparation of medicine for treating ankylosing spondylitis. Background technique [0002] Ankylosing spondylitis (AS) is a connective tissue disease characterized by chronic inflammation of the axial joints, mainly involving the spine and sacroiliac joints, leading to joint fibrosis and bony ankylosis, eventually leading to deformities. The disease can also involve internal organs and other tissues leading to chronic progressive rheumatism. Ankylosing spondylitis is more common in young men aged 16 to 30, and the incidence rate varies greatly in different regions and different races. The incidence rate of ankylosing spondylitis in my country is 0.3%. [0003] Clinically, patients with ankylosing spondylitis present with polyarticular lesions, and most of them first invade the sacroiliac joints and then develop upward to the cervical spine. In a small ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/433A61P29/00A61P19/04A61P19/02
Inventor 常晓天张云忠闫新峰韩金祥
Owner 常晓天
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com